Recombinant Human DPP4 protein(Ser484~Val728), His-tagged

• Cat.No.: DPP4-7872H
• Product Overview: Recombinant Human DPP4 protein(Ser484~Val728), fused with N-terminal His tag, was expressed in E.coli.

Specification

• Source: E.coli
• Species: Human
• Tag: N-His
• Protein length: Ser484~Val728
• Form: 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
• Bio-activity: Dipeptidyl peptidase-4 (DPP4), also known as adenosine deaminase complexing protein 2 or cluster of differentiation 26 (CD26), is a protein in humans. DPP4 is an antigenic enzyme expressed on the surface of most cell types and is associated with immune regulation, signal transduction and apoptosis. It is an intrinsic membrane glycoprotein and a serine exopeptidase that cleaves X-proline dipeptides from the N-terminus of polypeptides. Besides, Eosinophil Chemotactic Factor (ECF) has been identified as an interactor of DPP4, thus a binding ELISA assay was conducted to detect the interaction of recombinant human DPP4 and recombinant human ECF. Briefly, DPP4 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to ECF-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-DPP4 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50μL stop solution to the wells and read at 450nm immediately. The binding activity of DPP4 and ECF was shown in Figure, and this effect was in a dose dependent manner.
• Molecular Mass: 29.0kDa
• Endotoxin: <1.0EU per 1μg (determined by the LAL method).
• Purity: >95%
• Storage: Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
• Reconstitution: Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Gene Information

• Gene Name: DPP4 dipeptidyl-peptidase 4 [ Homo sapiens ]
• Official Symbol: DPP4
• Synonyms: DPP4; dipeptidyl-peptidase 4; ADCP2, adenosine deaminase complexing protein 2 , CD26, dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2); dipeptidyl peptidase 4; DPPIV; ADCP-2; DPP IV; dipeptidylpeptidase 4; dipeptidyl peptidase IV; T-cell activation antigen CD26; adenosine deaminase complexing protein 2; dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2); CD26; ADABP; ADCP2; TP103
• Gene ID: 1803
• mRNA Refseq: NM_001935
• Protein Refseq: NP_001926
• MIM: 102720
• UniProt ID: P27487

Reviews

09/13/2019

Its purity and efficacy make it an ideal choice for precise and accurate analysis, allowing me to generate reliable results.

01/27/2019

By incorporating the DPP4 Protein into their studies, scientists can confidently conduct their research, ushering in groundbreaking discoveries and novel insights within their respective domains.

12/14/2016

Its exceptional purity and functionality make it an ideal choice for accurate and precise analysis, ensuring reliable and reproducible results.

Q&As

How does DPP4 relate to diabetes?

DPP4 plays a crucial role in glucose homeostasis by cleaving incretin hormones. In diabetes, inhibiting DPP4 can enhance the action of these hormones, promoting insulin release and lowering blood sugar levels.

Are there any side effects associated with DPP4 inhibitors?

Common side effects of DPP4 inhibitors include respiratory and urinary tract infections, headache, and nasopharyngitis. However, they are generally well-tolerated.

What clinical applications does DPP4 have in managing type 2 diabetes?

Inhibitors of DPP4 are used in the treatment of type 2 diabetes to improve glycemic control. They work by prolonging the activity of incretin hormones, such as GLP-1, which stimulate insulin secretion.

Can DPP4 inhibitors be used as a monotherapy for diabetes?

DPP4 inhibitors are often used as monotherapy or in combination with other antidiabetic medications to achieve optimal glycemic control.

How do DPP4 inhibitors differ from other diabetes medications?

DPP4 inhibitors work by enhancing the effects of incretin hormones, while other diabetes medications may act on insulin sensitivity, insulin release, or glucose absorption.